biostudies-literatureUnknown20(1)Wang Y<h4>Background</h4>Poor graft function (PGF) or prolonged isolated thrombocytopenia (PT), which are characterized by pancytopenia or thrombocytopenia, have become serious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our previous single-arm trial suggests that N-acetyl-L-cysteine (NAC) prophylaxis reduced PGF or PT after allo-HSCT. Therefore, an open-label, randomized, phase 3 trial was performed to investigate the efficacy and tolerability of NAC prophylaxis to reduce PGF or PT after allo-HSCT.<h4>Methods</h4>A phase 3, open-label randomized trial was performed. Based on the percentage of CD34⁺VEGFR2 (CD309)⁺ endothelial cells (ECs) in bone marrow (BM) detected by flow cytometry at 14 days before conditioning, patients aged 15 toBMC medicine140https://www.ebi.ac.uk/biostudies/studies/S-EPMC9044574biostudies-literatureProphylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial.PMC9044574Zhang YYZhang XHHuang XJZhao HYXu LPLiu KYWang YKong YWang YZfalseProphylactic NAC promoted hematopoietic reconstitution by improving endothelial cells after haploidentical HSCT: a phase 3, open-label randomized trial.<h4>Background</h4>Poor graft function (PGF) or prolonged isolated thrombocytopenia (PT), which are characterized by pancytopenia or thrombocytopenia, have become serious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Our previous single-arm trial suggests that N-acetyl-L-cysteine (NAC) prophylaxis reduced PGF or PT after allo-HSCT. Therefore, an open-label, randomized, phase 3 trial was performed to investigate the efficacy and tolerability of NAC prophylaxis to reduce PGF or PT after allo-HSCT.<h4>Methods</h4>A phase 3, open-label randomized trial was performed. Based on the percentage of CD34⁺VEGFR2 (CD309)⁺ endothelial cells (ECs) in bone marrow (BM) detected by flow cytometry at 14 days before conditioning, patients aged 15 to2022-01-01T00:00:00Z2022 Apr2026-05-09T19:18:38.86Z2025-04-25T18:07:25.071ZS-EPMC90445743547380910.1186/s12916-022-02338-9